HWHao Wang

Hao Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hao Wang has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Hong-Zhuan Chen

    Shuguang Lab of Future Health, Shanghai Frontiers Science Center of TCM Chemical Biology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    11 shared publications
  • Chenghuan Song

    Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

    8 shared publications
  • Jiyun Shi

    Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi 214000, China

    8 shared publications
  • Wanying Huang

    Department of Pharmacology and Chemical Biology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    8 shared publications
  • Jing Wang

    Department of Pharmacology and Chemical Biology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    7 shared publications
  • Pingao Zhang

    Department of Pharmacology and Chemical Biology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    7 shared publications

Latest Publications

  • Open Access

    A biomimetic cryoprotectant preserves extracellular vesicles bioactivity for intravenous administration and potentiates wound healing

    by Pingao Zhang, Xinkai Nie, Hongwei Mao, Youyou Zhang, Jing Wang, Lufeng Wang, Rui Qin, Xiaoli Yang, Wanying Huang, Xiaoling Gao, et al.

    Extracellular vesicles (EVs) have emerged as promising vehicles for drug delivery and disease therapy owing to their intrinsic biocompatibility and capacit

  • A natural toolbox for brain delivery: Optimizing magnesium phosphate nanoparticles with “orifice-opening” compounds

    by Jing Wang, Chenghuan Song, Zijie Wei, Jiyun Shi, Pingao Zhang, Ting Yu, Wanying Huang, Lina Hou, Rui Zhang, Xiaoling Gao, et al.

  • Open Access

    Endothelium-specific endoglin triggers astrocyte reactivity via extracellular vesicles in a mouse model of Alzheimer’s disease

    by Pingao Zhang, Chenghuan Song, Jiyun Shi, Zijie Wei, Jing Wang, Wanying Huang, Rui Zhang, Jintao Wang, Xiaoli Yang, Gang Wang, et al.

    Background: Alzheimer’s disease (AD) is a multifaceted neurodegenerative disorder with a complex etiology that extends beyond the well-documented amyloid-β and tau pathologies. Growing evidence implicates cerebrovascular dysfunction, particularly brain microvascular endothelial cells (BMECs) dysfunction, as an early contributor to AD pathogenesis. However, how BMECs influence on neighboring astrocytes needs to be further explored. Methods: We employed a multi-omics approach integrating bulk RNA sequencing of human BMECs with proteomic analysis of cerebrospinal fluid (CSF) from AD patients and cerebrovascular endothelial extracellular vesicles (CEEVs). The role of identified candidate proteins was investigated in vitro and in vivo utilizing CEEVs transplantation and BMEC-astrocyte co-cultures. Endothelial cell-specific knockdown or treatment with a monoclonal antibody was used to assess the functional consequences on cognitive impairment and AD pathology via two-photon imaging and behavioral experiments on APP/PS1 mice. Results: The elevated endothelium-specific protein Endoglin (ENG) was identified in the brain and serum of AD individuals and APP/PS1 mice, and the supernatant of injured BMECs. ENG was released and delivered to adjacent astrocytes via CEEVs, and subsequently upregulated TGFBRI/Smad3 pathway in astrocytes, leading to astrocyte reactivity and the release of pro-inflammatory cytokines. Endothelial cell-specific ENG knockdown or treating with ENG monoclonal antibody Carotuximab significantly suppressed reactive astrocytes, reduced neuroinflammation, and improved cognitive performance of APP/PS1 mice. Conclusions: This study reveals a novel mechanism by which BMECs-derived ENG, delivered via CEEVs, drives astrocyte reactivity. These findings redefine the role of cerebrovascular dysfunction in AD pathogenesis and identify ENG as both a potential biomarker and a promising therapeutic target for AD.


  • Ginkgo biloba Extract GBE50 ameliorates cerebrovascular dysfunction and cognitive impairment in a mouse model of Alzheimer's disease

    by Ting Yu, Zijie Wei, Jing Wang, Chenghuan Song, Wanying Huang, Pingao Zhang, Jiyun Shi, Rui Zhang, Meifang Jiang, Dandan Wang, et al.


  • Open Access

    Microglial circDlg1 modulates neuroinflammation by blocking PDE4B ubiquitination-dependent degradation associated with Alzheimer's disease

    by Jiyun Shi, Chenghuan Song, Pingao Zhang, Jing Wang, Wanying Huang, Ting Yu, Zijie Wei, Lufeng Wang, Lanxue Zhao, Rui Zhang, et al.

    Background: Abnormal activation of microglia occurs in the early stage of Alzheimer's disease (AD) and leads to subsequent neuroinflammation and major AD pathologies. Circular RNAs (circRNAs) are emerging as great potential therapeutic targets in AD. However, the extent of circRNAs entwined and the underlying mechanism in microglia-driven neuroinflammation in AD remain elusive.


  • Open Access

    Dual Monitoring of Blood Acetylcholinesterase Content and Catalytic Activity Utilizing Fluorometry-Integrated Surface Plasmon Resonance

    by Yuanyuan Xie, Yifei Hou, Mengwei Hu, Hongzhuan Chen, Hao Wang, Lanxue Zhao, Jianrong Xu

    Acetylcholinesterase inhibitors (AChEIs), particularly donepezil, are commonly used to treat mild-to-moderate Alzheimer’s disease (AD). However, drug accumulation during long-term use could change AChE activity and content, leading to peripheral side effects and prompting medication discontinuation. However, there are a lack of methods to simultaneously determine the content and catalytic activity of AChE. By using phosphatidylinositol-specific phospholipase C to strip AChE from erythrocyte surfaces, we developed a novel method combining surface plasmon resonance and fluorescence detection for the simultaneous detection of AChE content and activity, producing stable, reliable, and accurate results. The established determination range spans from 263.37 ng/mL to 3000 ng/mL (4.05 nM to 46.15 nM) for concentration, and from 39.02 mU/mL to 1000 mU/mL for activity. Compared to traditional methods, this approach simplifies operations, reduces detection time, expands the dynamic range, and lowers detection limits, potentially advancing AChE-related research and supporting clinical diagnostics and drug development.


  • Open Access

    Artificial intelligence in medical problem-based learning: opportunities and challenges

    by Yaoxing Chen, Hong Qi, Yu Qiu, Juan Li, Liang Zhu, Xiaoling Gao, Hao Wang, Gan Jiang

    Problem-based learning (PBL) in medical education has encountered challenges affecting both teachers and students. The integration of artificial intelligence (AI) into PBL may provide potential solutions to these challenges. This paper aims to discuss the potential advantages of AI, where we found these merits of AI have the potential to improve the quality of PBL lessons. It is also important to pay attention to ethical guidelines and other limitations of AI in PBL lessons as well. Examples of interactions with AI chatbots are provided to demonstrate its application possibility. It is recommended to try using AI in PBL lessons, making it more adaptable for the PBL classroom. Future research should further explore the capabilities of AI, with the goal of developing a more personalized and adaptive learning experience within PBL.


  • Open Access

    Critical role of ROCK1 in AD pathogenesis via controlling lysosomal biogenesis and acidification

    by Chenghuan Song, Wanying Huang, Pingao Zhang, Jiyun Shi, Ting Yu, Jing Wang, Yongbo Hu, Lanxue Zhao, Rui Zhang, Gang Wang, et al.

    Background: Lysosomal homeostasis and functions are essential for the survival of neural cells. Impaired lysosomal biogenesis and acidification in Alzheimer’s disease (AD) pathogenesis leads to proteolytic dysfunction and neurodegeneration. However, the key regulatory factors and mechanisms of lysosomal homeostasis in AD remain poorly understood. Methods: ROCK1 expression and its co-localization with LAMP1 and SQSTM1/p62 were detected in post-mortem brains of healthy controls and AD patients. Lysosome-related fluorescence probe staining, transmission electron microscopy and immunoblotting were performed to evaluate the role of ROCK1 in lysosomal biogenesis and acidification in various neural cell types. The interaction between ROCK1 and TFEB was confirmed by surface plasmon resonance and in situ proximity ligation assay (PLA). Moreover, we performed AAV-mediated ROCK1 downregulation followed by immunofluorescence, enzyme-linked immunosorbent assay (ELISA) and behavioral tests to unveil the effects of the ROCK1–TFEB axis on lysosomes in APP/PS1 transgenic mice. Results: ROCK1 level was significantly increased in the brains of AD individuals, and was positively correlated with lysosomal markers and Aβ. Lysosomal proteolysis was largely impaired by the high abundance of ROCK1, while ROCK1 knockdown mitigated the lysosomal dysfunction in neurons and microglia. Moreover, we verified ROCK1 as a previously unknown upstream kinase of TFEB independent of m-TOR or GSK-3β. ROCK1 elevation resulted in abundant extracellular Aβ deposition which in turn bound to Aβ receptors and activated RhoA/ROCK1, thus forming a vicious circle of AD pathogenesis. Genetically downregulating ROCK1 lowered its interference with TFEB, promoted TFEB nuclear distribution, lysosomal biogenesis and lysosome-mediated Aβ clearance, and eventually prevented pathological traits and cognitive deficits in APP/PS1 mice. Conclusion: In summary, our results provide a mechanistic insight into the critical role of ROCK1 in lysosomal regulation and Aβ clearance in AD by acting as a novel upstream serine kinase of TFEB.


  • Open Access

    Ginkgo biloba Extract Drives Gut Flora and Microbial Metabolism Variation in a Mouse Model of Alzheimer’s Disease

    by Ting Yu, Yueyang Xing, Qi Gao, Dandan Wang, Hongzhuan Chen, Hao Wang, Yongfang Zhang

    Alzheimer’s disease (AD) is a complex neurodegenerative disease. Numerous investigations have demonstrated that medications that regulate the “brain–gut” axis can ameliorate disease symptoms of AD. Studies have shown that Ginkgo biloba extract (EGb) is involved in intestinal metabolism to meet the goal of illness treatment. EGb is currently utilized extensively in the clinical prevention and treatment of cardiovascular and cerebrovascular diseases. However, the regulatory effect of EGb on intestinal flora and its metabolites in AD pathology remains largely speculative. In this study, the Morris water maze test showed a significant improvement of spatial memory in the AD mouse model (APP/PS1 mice) after EGb treatment. We next confirmed the positive effects of EGb on the gut flora and metabolites of APP/PS1 mice and further showed that EGb treatment reshaped the disturbed gut microbiome, in particular by reducing the Firmicutes/Bacteroides ratio and increasing the abundance of Bacteroidetes, Uroviricota, Streptophyta, and Spirochaetes. Meanwhile, a non-targeted metabolomics analysis showed that EGb treatment significantly reversed the dysfunction of the microbial metabolic phenotype by altering Limosilactobacillus and Parvibacte, with 300 differential metabolites modulated (131 up-regulated, 169 down-regulated). Our findings highlight the significant regulatory impact of EGb on intestinal microflora and microbial metabolism in AD mice models and provide a potential therapeutic strategy for AD.


  • Smilagenin induces expression and epigenetic remodeling of BDNF in alzheimer's disease

    by Shuangshuang Yang, Lei Fan, Rui Zhang, Chenghuan Song, Jiyun Shi, Jing Wang, Pingao Zhang, Hao Wang, Yongfang Zhang